Massive NIH–industry project opens portals to target validation
Elie Dolgin • February 27, 2019
Five years in, the US$360 million Accelerating Medicines Partnership is yielding tools to speed up drug discovery for rheumatoid arthritis, lupus, diabetes, Alzheimer disease and Parkinson disease.
Continue reading at Nature Reviews Drug Discovery.
Molecular signatures of aging are changing how conservationists assess population health, resilience and risk.
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.